Michael Wang, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the one-year follow-up of ZUMA-2 (NCT02601313), a Phase II, registrational, multicenter study aiming to evaluate KTE-X19 therapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). In patients with a median follow-up of 17.5 months, the objective response rate was 92%, with a complete response (CR) rate of 67%. While common grade adverse events occurred in the majority of the study group, most of them were resolved and no treatment-related secondary cancers were identified. The ZUMA-2 study update highlights the clinical benefit of KTE-X19 therapy in R/R MCL patients, with results showing that most study participants achieved long-term CR with no severe adverse events being reported. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Dr Michael Wang has received grants from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, Juno, Loxo Oncology, VelosBio, BioInvent, Kite Pharma, Verastem, BeiGene, Eli Lilly, InnoCare and Molecular Templates; has received personal fees from Pharmacyclics, Celgene, Janssen, AstraZeneca/Acerta, OMI, Pulse Biosciences, Juno, Loxo Oncology, VelosBio, Targeted Oncology, Kite Pharma, Guidepoint Global, BeiGene, InnoCare and Oncternal; has received non-financial support from Pharmacyclics, Celgene, Janssen and OMI.